GGrantIndex
Sort

51,593 grants matching hepatitis

Endovascular Chemofiltration: Optimizing Removal of Chemotherapeutics and Nanoparticles from the Blood to Reduce Toxicity

$543,993
Steven William Hetts · University Of California, San Francisco · R01 · FY2015 · CA

Chlamydial Vaccine Testing in Mice and Guinea Pigs

$543,966
Nilu Goonetilleke · Univ Of North Carolina Chapel Hill · U19 · FY2019 · AI

Nanochelation Therapies for Iron Overload Disorders

$543,904
Jonghan Kim · Northeastern University · R01 · FY2019 · HL

(PQ8) Predicting immune-related toxicity in the adjuvant melanoma setting with checkpoint inhibition

$543,889
Iman Osman · New York University School Of Medicine · R01 · FY2019 · CA

Low Dose Interleukin-2 for Regulatory T cell Modulation and the Treatment of Crohn’s Disease

$543,883
Scott B Snapper · Boston Children'S Hospital · R01 · FY2023 · DK

Sterol Regulatory Element Binding Proteins in regulation of lipid metabolism

$543,851
Timothy F Osborne · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2014 · HL

CD4+ T Cells in Acute Versus Chronic HCV Infection

$543,750
Georg Michael Lauer · Massachusetts General Hospital · R01 · FY2015 · AI

Regulation of hepatic hepcidin expression by transferrin receptor-2

$543,687
Caroline Enns · Oregon Health & Science University · R01 · FY2022 · DK

Regulation of hepatic hepcidin expression by transferrin receptor-2

$543,687
Caroline Enns · Oregon Health & Science University · R01 · FY2023 · DK

Mechanisms Underlying the Pathogenesis of Non-alcoholic Fatty Liver Disease

$543,615
Yanqiao Zhang · University Of Arizona · R01 · FY2025 · DK

Protective and fibrosis-independent functions of hepatic stellate cells

$543,614
Robert F. Schwabe · Columbia University Health Sciences · R01 · FY2021 · DK

The Effects of Oxygen Therapy on Mouse Hepatitis Coronavirus Induced Pneumonia

$543,569
Parizad Torabi-Parizi · National Heart, Lung, And Blood Institute · ZIA · FY2023 · HL

Disturbed Crosstalk between Cholesterol Homeostasis and Inflammation Resolution in NASH

$543,526
Bishuang Cai · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · DK

HBV Capsid Effectors

$543,503
Raymond F. Schinazi · Emory University · R01 · FY2018 · AI

Molecular & cellular mechanisms of hepatocellular polarity and biliary secretion

$543,465
Irwin Arias · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2010 · HD

Dissecting the Role of Arachidonic Acid Metabolic Pathways Involved in Resolution Versus Progression of PM-Induced Cardiometabolic Toxicity

$543,455
Jesus Antonio Araujo · University Of California Los Angeles · R01 · FY2022 · ES

Impact of GLP-1 on Hepatic Fat and Energy Utilization in Obese Girls with Polycystic Ovarian Syndrome

$543,446
Melanie G Cree · University Of Colorado Denver · R01 · FY2021 · DK

Atherogenic Patheways Mediated by FOXO

$543,434
Domenico Accili · Columbia University Health Sciences · P01 · FY2008 · HL

Atherogenic Patheways Mediated by FOXO

$543,434
Domenico Accili · Columbia University Health Sciences · P01 · FY2011 · HL

Atherogenic Patheways Mediated by FOXO

$543,434
Domenico Accili · Columbia University Health Sciences · P01 · FY2010 · HL

Atherogenic Patheways Mediated by FOXO

$543,434
Domenico Accili · Columbia University Health Sciences · P01 · FY2009 · HL

Host response and liver disease in a hepatitis C-like virus rat model

$543,426
Amit Kapoor · Research Inst Nationwide Children'S Hosp · R01 · FY2018 · AI

The UPR and CaMKIIg in Atherosclerosis and Insulin Resistance

$543,352
Ira A Tabas · Columbia University Health Sciences · P01 · FY2017 · HL

The UPR and CaMKIIg in Atherosclerosis and Insulin Resistance

$543,352
Ira A Tabas · Columbia University Health Sciences · P01 · FY2016 · HL

The UPR and CaMKIIg in Atherosclerosis and Insulin Resistance

$543,351
Ira A Tabas · Columbia University Health Sciences · P01 · FY2013 · HL